Organigram Holdings Inc. (OTCQX: OGRMF) announced on September 13th the company has closed its $10 million investment into Hyasynth Biologicals Inc. (Hyasynth). Hyasynth is a cannabis company focused on biological technology and is currently a leader in cannabinoid biotechnology.

This $10 million investment from Organigram is intended to be used toward Hyasynth’s process of converting yeast strains that are genetically modified into phytocannabinoids and compounds that share a close molecular structure to phytocannabinoids.

Leave a Reply